The Geriatric Medicine SCE requires broad specialty knowledge and the ability to choose between plausible actions for an older person with interacting clinical problems. Preparation should connect the examination framework to clinical reasoning, medicines review, function, patient priorities and uncertainty. Completing a large bank is useful only when the explanations change how you approach the next case.
Examination information in this guide was checked on 3 October 2026. The next listed sitting is 21 October 2026, not 16 September. The latter date belongs to other specialty examinations and should not be used to plan Geriatric Medicine preparation. The Federation's specialty page is the authoritative starting point.
Examination dates, applications and fees
The Federation lists two Geriatric Medicine sittings in the 2026 calendar: 4 February, which has passed, and 21 October. Applications for October ran from 1 to 29 July 2026, with a reasonable-adjustment deadline of 5 August. The published results timetable is approximately six weeks after the examination. These are sitting and application dates, not a claim that late places remain available.
Do not extrapolate a permanent February-and-October pattern from that calendar. As checked on 3 October 2026, the specialty page describes delivery every nine months and lists the next examination after October on 21 July 2027. Candidates planning beyond the current sitting should use the live timetable rather than an assumed twice-yearly schedule.
The published SCE fees, checked on 3 October 2026, are £700 for a UK centre and £875 for an international centre. These are examination fees, separate from any revision subscription. Review the applicable withdrawal, transfer and refund conditions before making a booking; do not assume cancellation after the application deadline produces a refund.
Format and the level of knowledge required
The published examination format comprises two papers of 100 best-of-five single-best-answer questions, with three hours for each paper and a one-hour break between them. There are 200 questions across the day. From June 2026, the Federation states that UK and international SCE sittings are delivered in centre. Your allocation and current candidate instructions determine the practical arrangements.
Questions can test recognition, interpretation and the selection of an appropriate next step. A familiar diagnosis does not settle a question about investigation, function, rehabilitation or a patient's priorities. Practise identifying the decision being requested before comparing the options.
The Federation's eligibility guidance, checked on 3 October 2026, states that there are no entry requirements. It advises UK dual-accrediting trainees to consider an initial attempt during ST5, and single-accreditation trainees may consider ST4. The often-used ST5 to ST7 revision window is a planning convention, not an eligibility rule. Discuss timing with your programme rather than assuming that being near CCT is a prerequisite to enter.
Curriculum coverage and a practical study allocation
Use the official curriculum and blueprint to establish the assessed scope. The following table retains iatroX's published twelve-theme study allocation, checked on 3 October 2026. It is an illustrative allocation for a 200-question revision set, not a verified reproduction of the official paper's topic counts or a prediction of the October questions.
| Revision theme | Illustrative questions | Share of this study set |
|---|---|---|
| Frailty, falls and comprehensive geriatric assessment | 28 | 14% |
| Dementia and delirium, including recognition and treatment principles | 26 | 13% |
| Stroke and TIA, secondary prevention and rehabilitation | 20 | 10% |
| Parkinson's disease, atypical parkinsonism and drug-induced movement disorders | 16 | 8% |
| Polypharmacy, STOPP/START, anticholinergic burden and deprescribing | 18 | 9% |
| Urinary and faecal continence, including post-stroke problems | 12 | 6% |
| Osteoporosis, fracture liaison and fragility-fracture management | 14 | 7% |
| Acute presentations, including infection, kidney injury, syncope and arrhythmia | 18 | 9% |
| End-of-life care, capacity, deprivation of liberty and advance planning | 18 | 9% |
| Pressure ulcers, sarcopenia, nutrition, dysphagia and oral health | 12 | 6% |
| Intermediate care, hospital at home, virtual wards and front-door frailty services | 10 | 5% |
| Statistics, ethics and professional behaviours | 8 | 4% |
The allocation can help expose neglected areas, but your learning needs may justify a different distribution. Do not let question-bank item density become a claim about where the examining body will allocate marks. The official framework and your performance on unfamiliar material should remain visible alongside any adaptive recommendations.
High-value review themes and the sources they need
Comprehensive geriatric assessment should connect medical, functional, psychological, social and environmental information. The BGS primary-care CGA toolkit provides a useful structure for reviewing those domains. When reading research, including Cochrane work on CGA, ask which setting and population were studied rather than carrying a general benefit claim into every service model.
For delirium, compare the purpose of the 4AT and CAM with the clinical history of onset and fluctuation. Keep screening, diagnosis, prevention and management distinct. Review what a locally used TIME approach addresses rather than treating its name as a universal prevention protocol. Any discussion of antipsychotics should include the specific indication, risks and monitoring, not an assumption that agitation requires medication.
For falls, connect the history to medication review, postural symptoms, environmental factors and function. NICE's current falls guidance is NG249, replacing the older CG161 reference. STEADI is a separate framework and should not silently replace UK recommendations. Check the current NICE guidance for the population and setting relevant to the question.
Medicines revision should compare the roles and limitations of donepezil, rivastigmine, galantamine and memantine rather than memorising an undifferentiated dementia-drug list. Anti-amyloid treatments such as lecanemab and donanemab raise additional questions about eligibility, biomarkers, monitoring and amyloid-related imaging abnormalities. Verify current regulatory and NICE positions through the original documents; being a prominent research topic does not prove that it will appear in this sitting.
For Parkinson's disease, organise revision around the problem being addressed: wearing-off, adverse effects, non-motor symptoms, psychosis or later-stage care. Entacapone, opicapone, safinamide, istradefylline, deep brain stimulation, quetiapine and pimavanserin appear in different treatment discussions internationally. Their appearance in a learning list is not a statement that they are interchangeable, universally available or all recommended for the same UK patient. Check current guidance and authorised product information before interpreting a management question.
End-of-life topics include anticipatory planning, route changes, opioid-conversion principles, terminal agitation and respiratory secretions. Midazolam and glycopyrronium are examples of medicines that may arise in that reading, but the learning task is to establish purpose, appropriateness, monitoring and the relevant prescribing source. This guide does not provide dosing instructions.
Capacity and deprivation of liberty need current sources
Revise decision-specific capacity, support for decision-making, best interests and the different authority held by a health-and-welfare attorney or a court-appointed deputy. In England and Wales, the functional assessment concerns understanding, retention, use or weighing of relevant information, and communication. Do not assume that a diagnosis or disagreement alone establishes incapacity. Use the GMC's decision-making and consent guidance and the applicable legal framework.
An old statement that Liberty Protection Safeguards began replacing DoLS in 2024 should not be learned as fact. The government's 18 October 2025 announcement described a consultation planned for 2026. The GMC subsequently updated its consent guidance on 3 August 2026 following the UK Supreme Court's 2026 deprivation-of-liberty judgment. Those developments make undated summaries particularly unsuitable for current revision.
For a hypothetical hospital, care-home or domestic-care scenario, identify the jurisdiction, proposed arrangements, person's circumstances and relevant current source. Do not collapse the question into recalling which acronym follows another. Where a consequential legal interpretation remains uncertain, seek appropriate professional advice rather than treating an AI explanation as the authority.
Common pitfalls: seven checks worth making
First, check the version of STOPP/START in an older resource. Version 3 was published in May 2023; an explanation based on a previous version needs examination rather than automatic acceptance. Compare STOPP/START with the purpose and jurisdiction of the Beers criteria instead of treating them as identical lists.
Second, distinguish dementia syndromes through the supplied pattern. Lewy body disease, behavioural-variant frontotemporal dementia, vascular cognitive impairment and Alzheimer's disease should not become interchangeable answers simply because cognitive decline appears in the stem. Explain which feature makes an alternative less persuasive, and verify uncertain distinctions in the appropriate source.
Third, keep capacity and deprivation-of-liberty revision dated, as above. Fourth, compare the intended use of the Clinical Frailty Scale, electronic Frailty Index, PRISMA-7 and gait-speed assessment. They are not merely different ways to produce an equivalent number.
Fifth, when reviewing anti-amyloid treatments, distinguish ARIA-E from ARIA-H and understand why APOE-e4 status may be relevant to a source's discussion. Do not substitute remembered eligibility or monitoring details for the current document. Sixth, distinguish stress, urge, mixed, overflow and functional continence problems before reviewing medication options. A comparison involving mirabegron, oxybutynin or solifenacin needs the actual indication, risks and current recommendations, not a blanket preferred-drug slogan.
Seventh, review how geriatric research reports outcomes. Composite fall outcomes, fracture-trial hazard ratios, FREEDOM, ARCH, romosozumab research and CGA reviews provide different opportunities to practise interpretation. The purpose is to identify what an estimate establishes, not to memorise a trial name as the answer. These are suggested error checks, not quantified findings from a defined cohort of successful candidates.
A twelve-week revision plan that can be adapted
For weeks one to four, sample all twelve themes and identify the concepts requiring explanation. The original iatroX planning example used 30 questions per day; treat that as an optional workload, not a validated target. A shorter session with careful review may be more useful than completing an ambitious quota without understanding the errors.
During weeks five to eight, prioritise recurring gaps while retaining mixed practice. Use relevant BGS statements and STOPP/START material selectively. ECG interpretation, bone-profile interpretation and anticholinergic-burden exercises can be included where your practice shows a need. Avoid turning a suggestion to read authoritative material into a requirement to read every statement regardless of relevance.
Weeks nine to eleven introduce fuller timed practice. Two 200-question mocks per week represent an intensive version of the plan, not a minimum standard. Reserve time for debriefing and reduce the number when another mock would displace the correction it identifies. Include capacity reasoning and prescribing principles without mistaking a commercial score for an official pass prediction.
In week twelve, use bookmarks and a short error summary, check genuinely relevant guidance changes, and confirm your examination arrangements. Do not begin an extensive new resource simply because the examination is close. This is a proposed planning framework, not an observed programme with a demonstrated pass rate.
For the 21 October 2026 sitting, a new twelve-week programme is no longer the right starting point. Use the remaining period to repair selected weaknesses, retain breadth and practise the current format. iatroX's dedicated final-fortnight Geriatric Medicine article develops that narrower approach.
Sample reasoning: recognising an extreme refeeding-risk presentation
Consider a fictional teaching version of the bank's displayed nutrition case: an older adult weighs 42 kg, has a BMI of 13.6 kg/m2 and has had negligible intake for 17 days. Circulation has been stabilised and enteral feeding is planned. The task here is to identify the appropriate risk-management approach, rather than calculate a prescription.
Compare five possible approaches: begin feeding and add cardiac monitoring only if phosphate subsequently falls; delay thiamine until after feeding starts; recognise the extreme-risk presentation and use a carefully supervised plan with appropriate vitamin support and continuous cardiac monitoring; omit supplementation because initial electrolytes appear normal; or assume that older age itself reduces refeeding risk.
The third approach captures the relevant principle in NICE CG32's nutrition-support recommendations, checked on 3 October 2026. The case should lead you to the original recommendations and an appropriately trained nutrition-support team, not to an improvised regimen. Normal baseline results do not, by themselves, remove the concern created by the history. No dose or initial energy prescription is supplied here.
After reviewing, change one feature and explain whether the same reasoning still applies. The useful learning outcome is recognition of the risk and its consequences for planning, not recognition of the answer's position in a familiar multiple-choice item.
Using iatroX without confusing product design with examination evidence
In its published product information checked on 3 October 2026, iatroX describes more than 1,000 Geriatric Medicine questions, developed with UK geriatrician input and organised against the specialty framework. Adaptive sequencing, topic-based performance information, spaced repetition and timed mocks are learning features. They do not establish that every question or generated explanation is correct, that the bank exactly reproduces the official blueprint weights, or that completion predicts a pass.
The Socratic Tutor begins with a question you attempted and uses targeted follow-up questions to explore the misconception. A useful session ends when you can explain the distinction and apply it to a different case. Checking the original clinical source remains important when an explanation concerns a changeable recommendation or an uncertain interpretation.
Ask-iatroX and free question access have no trial expiry or verification gate, per iatroX product information dated 3 October 2026. The public sample offers up to 20 questions without an account. A separate, limited guided Tutor demonstration is described for verified accounts; that condition does not apply to the free questions. Ongoing tutoring is part of the paid subscription.
As published on 3 October 2026, the UK subscription is £99 paid upfront for a year, equivalent to £8.25 per month billed annually, or £29 monthly. Question banks, Socratic Tutor, study planner, simulations and CPD tools are included together. The page also advertises separate US-dollar prices of $29 monthly and $99 annually; these are not currency conversions or Australian-dollar quotations. The published offer mentions cancellation and a seven-day annual money-back guarantee; check the purchase terms and billing channel for the arrangement that applies to you.
Related examinations and continuing learning
BGS membership is separate from the SCE qualification, although its educational resources can support preparation. Passing this written specialty assessment is also distinct from demonstrating every practical and professional competency required for training completion. Discuss your programme's requirements with the relevant training team.
The iatroX catalogue also contains MRCP(UK) Part 1, Palliative Medicine SCE and DGM learning pathways. They may address a relevant prerequisite or subsequent goal, but access to unrelated examinations is not the reason to choose a resource for this sitting. Use the tools that address your actual geriatric learning needs.
The original hub's clinical-review credit names Dr Kola Tytler, MBBS CertHE MBA MSt MRCGP, with a review date of 12 May 2026. The examination and product checks in this revision are dated 3 October 2026; that is not a claim of a new personal clinical sign-off. The platform's methodology explains its approach and limitations.
Frequently asked questions
When is the next Geriatric Medicine SCE?
The Federation lists 21 October 2026, with applications having closed on 29 July. Its next published date after that is 21 July 2027, so do not assume a permanent twice-yearly pattern.
Does the study-allocation table reproduce the official examination blueprint?
No: it is an illustrative iatroX revision allocation retained to support coverage planning. Use the Federation's current curriculum and blueprint to establish the official assessment scope.
Is the full Geriatric Medicine bank free?
Free questions and Ask-iatroX remain available without trial expiry, but the full premium bank and ongoing Tutor are paid. The subscription includes the other supported learning methods together, rather than charging separately for simulations or CPD.